查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941555

心房顫動市場規模、佔有率和趨勢分析報告：按療法、最終用途、地區和細分市場預測（2026-2033 年）

Atrial Fibrillation Market Size, Share & Trends Analysis Report By Treatment (Pharmacological Treatment, Non Pharmacological Treatment), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

心房顫動市場概覽

2025年全球心房顫動市場規模估計為295.2億美元，預計2033年將達到653.3億美元。

預計從 2026 年到 2033 年，該市場將以 10.52% 的複合年成長率成長。推動該市場成長的因素包括疾病負擔加重、治療和診斷技術的快速發展以及向遠端患者監護的轉變。

能夠將這些先進技術整合到綜合護理解決方案中的公司，並有望主導市場成長，因為臨床實踐正在向更有效率、以患者為中心的模式轉型。旨在擴大創新療法應用範圍的策略聯盟和收購將進一步加劇市場競爭。

人口老化以及高血壓、糖尿病和肥胖等風險因素的增加，導致心房顫動盛行率不斷上升，這是市場成長的關鍵促進因素。心房顫動是中風和心臟衰竭的主要原因之一，醫療系統優先考慮早期診斷和有效治療。患者數量的成長直接推動了對藥物治療和先進介入療法的需求。 2024年5月，美國疾病管制與預防中心（CDC）將心房顫動（心房顫動）列為美國最常見的需要治療的心律不整。預計到2030年，美國房顫患者人數將達1,210萬人。心房顫動每年導致約15.8萬人死亡，約佔中風病例的七分之一。

心導管電氣燒灼術、3D電解剖標測和穿戴式心電圖（ECG）監測等技術的進步正在提高心房顫動治療的準確性和安全性。人工智慧（AI）在心律不整檢測和治療計畫中的應用，實現了更快、更準確的診斷和標靶治療。這些創新不僅為更多患者提供了治療選擇，還改善了治療效果並降低了復發率。據美國心律學會（HRS）稱，在2025年4月舉行的「心律2025」會議上發表的新研究表明，人工智慧（AI）正在提高心房顫動（AFib）治療的安全性和成功率。人工智慧驅動的DeePRISM模型能夠在消融手術過程中進行即時波形分析，進而改善持續性心房顫動患者的治療效果。專家強調了人工智慧透過提高臨床信心和手術準確性來改變電生理學的潛力。

遠端監測和遠端醫療平台的應用正在改變心房顫動的管理方式，使臨床環境以外的持續心律監測成為可能。穿戴式心電圖設備和智慧型手機應用程式可為患者和醫生提供即時數據，從而支援主動管理和早期療育。醫療服務提供者正在利用這些工具有效地監測更多患者，尤其是在術後追蹤和長期照護方面。 2025年5月，墨爾本腦中心的研究人員開發了人工智慧模型，該模型能夠利用腦部MRI影像分析檢測中風患者的無症狀性心房顫動。這項技術在區分心房顫動相關性中風方面展現出較高的準確率（AUC 0.81），提供了一種非侵入性且高效的檢測方法。透過識別需要進一步心臟評估的亞臨床心房顫動病例，這種方法可能有助於更快診斷和更個人化的中風治療。

叢集柱狀圖顯示了1990年至2021年間美洲地區與心律不整相關的傷殘調整壽命年（DALYs）和死亡率的逐步上升。 DALYs從每10萬人117.14增至120.68，死亡率從每10萬人4.18增加到4.84。這反映出醫療保健系統持續面臨日益成長的壓力，尤其是在早期檢測和先進治療機會仍然不均的地區。如果不採取有針對性的醫療保健政策來消除這些區域差異，預計未來幾十年心房顫動的臨床和經濟負擔將進一步加重。

心房顫動（心房顫動）是全球最常見的持續性心律不整，由於其與中風、心臟衰竭和死亡風險增加有關，因此為醫療保健系統帶來了巨大挑戰。儘管治療方法不斷進步，但由於人口老化和生活方式相關的危險因素，過去30年全球心房顫動盛行率增加了一倍以上。根據2025年7月出版的《柳葉刀區域健康美洲》雜誌，區域差異持續影響整個美洲大陸心房顫動的負擔。美國心房顫動發生率和盛行率增幅最大，而加拿大則出現了年齡調整後的下降。中等收入國家佔心房顫動病例的大多數，且在篩檢能力有限的情況下，其發生率仍在上升。解決這些系統性差異對於減輕心房顫動在該地區日益嚴重的臨床和經濟影響至關重要。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 全球心房顫動市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關市場展望
  • 市場動態
  • 全球心房顫動市場分析工具
    • 產業分析：波特五力模型
    • PESTLE分析
  • 科技趨勢
  • 案例研究分析

第4章 全球心房顫動市場細分分析（依治療方法分類，2021-2033 年）

  • 定義和範圍
  • 按療法分類的市場佔有率分析（2025 年和 2033 年）
  • 2021-2033年全球心房顫動市場（依治療方法分類）
  • 藥物治療
  • 非藥物療法

5. 全球心房顫動市場細分分析（依最終用途分類，2021-2033 年）

  • 定義和範圍
  • 按最終用途分類的市場佔有率分析（2025 年和 2033 年）
  • 2021-2033年全球心房顫動市場（依最終用途分類）
  • 醫院
  • 專科診所
  • 其他

6. 2021-2033年按地區分類的心房顫動市場細分

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 區域市場概覽
  • 2025年及2033年各地區心房顫動市場佔有率：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第7章 競爭情勢

  • 對主要市場參與企業近期趨勢和影響的分析
  • 公司分類
  • 公司簡介
    • AtriCure Inc.
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation.
    • Bristol-Myers Squibb Corporation
    • Cardio Focus Inc.
    • Sanofi Aventis
    • Biosense Webster Inc.
    • Endoscopic Technologies Inc.
    • Abbott（St. Jude Medical Inc.）
    • Johnson &Johnson
Product Code: 978-1-68038-004-0

Atrial Fibrillation Market Summary

The global atrial fibrillation market size was estimated at USD 29.52 billion in 2025 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.52% from 2026 to 2033. The market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.

Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.

The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.

Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI's potential to transform electrophysiology by boosting clinical confidence and procedural precision.

The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.

The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF's escalating clinical and economic impact in the region.

Global Atrial Fibrillation Market Report Segmentation

This report forecasts revenue growth and provides a global, regional, and country level analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment, end use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacological Treatment
    • Anti-arrhythmic Drugs
    • Anticoagulant Drugs
  • Non-Pharmacological Treatment
    • Catheter Ablation
    • Radiofrequency
    • HIFU
    • Cryoablation
    • Microwave
    • Laser
    • Maze Surgery
    • Electric Cardioversion
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment scope
    • 1.1.2. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. Research Assumptions
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End use outlook
  • 2.3. Competitive Insights

Chapter 3. Global Atrial Fibrillation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Global Atrial Fibrillation: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTLE Analysis
  • 3.4. Technology Landscape
  • 3.5. Case Study Analysis

Chapter 4. Global Atrial Fibrillation Market Segment Analysis, By Treatment, 2021-2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Treatment Market Share Analysis, 2025 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global Atrial Fibrillation Market, by Treatment, 2021 to 2033
  • 4.5. Pharmacological Treatment
    • 4.5.1. Pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.2. Anti-arrhythmic Drugs
      • 4.5.2.1. Anti-arrhythmic drugs market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.3. Anticoagulant Drugs
      • 4.5.3.1. Anticoagulant drugs market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Non-Pharmacological Treatment
    • 4.6.1. Non-pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2. Catheter Ablation
      • 4.6.2.1. Catheter ablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.2. Radiofrequency
        • 4.6.2.2.1. Radiofrequency market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.3. HIFU
        • 4.6.2.3.1. HIFU market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.4. Cryoablation
        • 4.6.2.4.1. Cryoablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.5. Microwave
        • 4.6.2.5.1. Microwave market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.6. Laser
        • 4.6.2.6.1. Laser market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.3. Maze Surgery
      • 4.6.3.1. Maze surgery market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.4. Electric Cardioversion
      • 4.6.4.1. Electric cardioversion market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Atrial Fibrillation Market Segment Analysis, By End Use, 2021-2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. End Use Market Share Analysis, 2025 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Global Atrial Fibrillation Market, by End Use, 2021 to 2033
  • 5.5. Hospitals
    • 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Specialty Clinics
    • 5.6.1. Specialty Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Atrial Fibrillation Market Segment Analysis, By Region, 2021- 2033 (USD Million)

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Atrial Fibrillation Market Share by Region, 2025 & 2033:
  • 6.5. North America
    • 6.5.1. North America atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Scenario
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. U.S. atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Scenario
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Canada atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Scenario
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Mexico atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Scenario
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. UK atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Scenario
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Germany atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Scenario
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. France atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Scenario
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Italy atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Scenario
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Spain atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Scenario
      • 6.6.7.3. Competitive Scenario
      • 6.6.7.4. Norway atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key Country Dynamics
      • 6.6.8.2. Regulatory Scenario
      • 6.6.8.3. Competitive Scenario
      • 6.6.8.4. Sweden atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key Country Dynamics
      • 6.6.9.2. Regulatory Scenario
      • 6.6.9.3. Competitive Scenario
      • 6.6.9.4. Denmark atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Scenario
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Japan atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Scenario
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. China atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Scenario
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. India atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Regulatory Scenario
      • 6.7.4.3. Competitive Scenario
      • 6.7.4.4. Australia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Regulatory Scenario
      • 6.7.5.3. Competitive Scenario
      • 6.7.5.4. South Korea atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Regulatory Scenario
      • 6.7.6.3. Competitive Scenario
      • 6.7.6.4. Thailand atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Scenario
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. Brazil atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Scenario
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Argentina atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key Country Dynamics
      • 6.9.1.2. Regulatory Scenario
      • 6.9.1.3. Competitive Scenario
      • 6.9.1.4. South Africa atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Regulatory Scenario
      • 6.9.2.3. Competitive Scenario
      • 6.9.2.4. Saudi Arabia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Regulatory Scenario
      • 6.9.3.3. Competitive Scenario
      • 6.9.3.4. UAE atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key Country Dynamics
      • 6.9.4.2. Regulatory Scenario
      • 6.9.4.3. Competitive Scenario
      • 6.9.4.4. Kuwait atrial fibrillation market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Profiles
    • 7.3.1. AtriCure Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Boehringer Ingelheim GmbH
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Boston Scientific Corporation.
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Bristol- Myers Squibb Corporation
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Cardio Focus Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Sanofi Aventis
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Biosense Webster Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Endoscopic Technologies Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Abbott (St. Jude Medical Inc.)
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Johnson & Johnson
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Atrial Fibrillation Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 4 Global Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 5 Global Atrial Fibrillation Market, By Region, 2021 - 2033, (USD Million)
  • Table 6 North America Atrial Fibrillation Market, By Country, 2021 - 2033, (USD Million)
  • Table 7 North America Atrial Fibrillation Market, By Treatment, 2021 - 2033 (USD Million)
  • Table 8 North America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 9 U.S. Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 10 U.S. Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 Canada Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 12 Canada Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 Mexico Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 14 Mexico Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15 Europe Atrial Fibrillation Market, by Country, 2021 - 2033, (USD Million)
  • Table 16 Europe Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 17 Europe Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18 UK Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 19 UK Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Germany Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 22 France Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 23 France Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 Italy Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 26 Spain Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28 Denmark Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 29 Denmark Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 Sweden Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 31 Sweden Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 32 Norway Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 33 Norway Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37 Japan Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 38 Japan Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 China Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 40 China Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 41 India Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 42 India Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43 Australia Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 44 Australia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Thailand Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 46 Thailand Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 47 South Korea Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 48 South Korea Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49 Latin America Atrial Fibrillation Market, by Country, 2021 - 2033, (USD Million)
  • Table 50 Latin America Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 51 Latin America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Brazil Atrial Fibrillation Market, by Treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Argentina Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 55 Argentina Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Atrial Fibrillation Market, by Country, 2021 - 2033, (USD Million)
  • Table 57 Middle East & Africa Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 58 Middle East & Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59 South Africa Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 60 South Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 62 Saudi Arabia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 63 UAE Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 64 UAE Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Atrial Fibrillation Market, by Treatment, 2021 - 2033, (USD Million)
  • Table 66 Kuwait Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Global atrial fibrillation market: outlook
  • Fig. 9 Global atrial fibrillation competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Ancillary market outlook
  • Fig. 12 Global atrial fibrillation market driver impact
  • Fig. 13 Global atrial fibrillation market restraint impact
  • Fig. 14 Porter's Analysis
  • Fig. 15 PESTLE Analysis
  • Fig. 16 Global atrial fibrillation market: Treatment movement analysis
  • Fig. 17 Global atrial fibrillation market: Treatment outlook and key takeaways
  • Fig. 18 Pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 19 Anti-arrhythmic drugs market estimates and forecast, 2021 - 2033
  • Fig. 20 Anticoagulant drugs market estimates and forecast, 2021 - 2033
  • Fig. 21 Non-pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 22 Catheter ablation market estimates and forecast, 2021 - 2033
  • Fig. 23 Radiofrequency market estimates and forecast, 2021 - 2033
  • Fig. 24 HIFU market estimates and forecast, 2021 - 2033
  • Fig. 25 Cryoablation market estimates and forecast, 2021 - 2033
  • Fig. 26 Microwave market estimates and forecast, 2021 - 2033
  • Fig. 27 Laser market estimates and forecast, 2021 - 2033
  • Fig. 28 Maze surgery market estimates and forecast, 2021 - 2033
  • Fig. 29 Electric cardioversion market estimates and forecast, 2021 - 2033
  • Fig. 30 Global atrial fibrillation market: End use movement analysis
  • Fig. 31 Global atrial fibrillation market: End use outlook and key takeaways
  • Fig. 32 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 33 Specialty clinics market estimates and forecasts, 2021 - 2033
  • Fig. 34 Others market estimates and forecasts, 2021 - 2033
  • Fig. 35 Global atrial fibrillation market: Regional movement analysis
  • Fig. 36 Global atrial fibrillation market: Regional outlook and key takeaways
  • Fig. 37 North America atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 UK atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Germany atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Asia Pacific atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Japan atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 China atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 India atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Australia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Brazil atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Argentina atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 MEA atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key company categorization
  • Fig. 89 Heat map analysis 2025